Genomic Expression Is Presenting Their Next Generation Diagnostic Platform for Personalized Medicine At MADV's Venture Forum Friday December 9th

Online, December 3, 2011 (Newswire.com) - Genomic Expression is a genomics tool and diagnostic company developing a Next Generation Diagnostic Platform for Personalized Medicine. Our technology is based on a platform agnostic intelligent target filtering technology integrated with sequencing short reads on a small chip, addressing the bottlenecks in the current sequencing platforms.

The platform is the most cost effective high resolution solution technology available/actionable marker. Genomic Expression has access to 15 million biological samples associated with cradle-to-grave electronic medical records as the diagnostic partner of a recently $30 million grant funded consortium in Denmark focusing on cancer.

There are 800 cancer compounds in the clinic and all of them work on a small subset of patients. Cancer is a random genetic disease. "Our chances of curing cancer increases dramatically if we can detect early, select the most efficient drug for the individual patient and monitor treatment using Next Generation Diagnostics." states Gitte Pedersen, CEO. That has until now been very time consuming and expensive.

On average it takes 10 years from discovery of a biomarker to it is applied in the clinic. Genomic Expressions Diagnostic Platform for Personal Medicine is changing the current biomarker discovery paradigm, resulting in savings of $20 million and several years.

"Our vision is that personalized medicine can create a better and more efficient healthcare system. We will become the diagnostic platform of choice due to our technology's flexibility, robustness, and attractive price point", says Gitte Pedersen, CEO.

As a part of the $30 million grant project, Genomic Expression has access to lab space, equipment, top researchers, the largest bioinformatics institute in Europe, and 15 million biological samples linked to cradle-to-grave electronic medical records, making the company very capital efficient.

About Mid-Atlantic Diamond Ventures (MADV)
Mid-Atlantic Diamond Ventures (MADV) provides support and connections to capital to early-stage innovation and knowledge-based businesses seeking Series A financing. It is the only year 'round venture forum program in the Greater Philadelphia area (four forums annually), and serves emerging firms throughout the Mid-Atlantic region. The program is also one of the largest by number of clients served: about 40 high-quality entrepreneurs in life science, information technology and physical sciences each year.